Jim Cramer sees signs everywhere that the worst is over for pharma.
Discussing the M&A space for biotech and health care with Les Funtleyder, Asset Management Portfolio Manager at ESquared, and Michael Yee, BioTech Analyst at RBC Capital Markets
Abbott Labs said it agreed to St. Jude Medical for $25 billion to add heft to its heart and neurological devices business.
CNBC contributor and Former Medtronic CEO Bill George reacts to the merger between St. Jude Medical and Abbott Labs.
Abbott Labs Chairman and CEO Miles White, explains the timing behind the merger with St. Jude Medical.
Abbott Labs Chairman and CEO Miles White discusses whether the company looked at inversion, after announcing a deal to buy St. Jude Medical.
Abbott Labs is buying St. Jude Medical for $25 billion. Abbott Labs Chairman and CEO Miles White, discusses the fit for both companies.
CNBC's David Faber reports Abbott Labs is agreeing to buy St. Jude Medical in a cash and stock deal. CNBC's Jim Cramer, weighs in.
Some of the names on the move ahead of the open.
Dane Leone, BTIG analyst, discusses Abbott Labs' $25 billion dollar bid for St. Jude for about $85 per share.
Abbott Laboratories is making a $25 billion bid for St. Jude, reports the "Squawk Box" crew.
Jim Cramer explains what to watch ahead of the open including Abbott Labs' quarterly report.
U.S. stock index futures indicated a flat open with investors digesting the results of the New York primaries.
CNBC's David Faber reports Abbott Labs is announcing it will buy diagnostics company Alere for $5.8 billion.
U.S. stock index futures indicated a mixed open Thursday after December durable goods orders declined far more than expected.
Pfizer's proposed acquisition of Allergan will be one of the biggest tax inversions yet.
China's easing of the one-baby rule may not be enough to cure its slowing fertility rate and aging population problem.
A hot sports car stock could leave a group of blue chips in its dust, as traders watch earnings reports to see if corporate profits are cooling.
So far the earnings season has been lackluster, and some high-profile warnings have already given investors pause.
Here's why there could be a "surprising" stock market rally in the fourth quarter, strategist Brian Belski said Monday.